• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • hRPCs for Retinal Disease
    • CTX cells for Stroke Disability
    • CTX-derived Exosomes
    • Induced pluripotent stem cell (iPSC) Platform
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I/IIa clinical trial in retinitis pigmentosa
    • Phase IIb Clinical trial in stroke disability (PISCES III)
    • Phase IIa clinical trial in stroke disability (PISCES-II)
    • Phase I clinical trial in stroke disability (PISCES)
    • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • hRPCs for Retinal Disease
    • CTX cells for Stroke Disability
    • CTX-derived Exosomes
    • Induced pluripotent stem cell (iPSC) Platform
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I/IIa clinical trial in retinitis pigmentosa
    • Phase IIb Clinical trial in stroke disability (PISCES III)
    • Phase IIa clinical trial in stroke disability (PISCES-II)
    • Phase I clinical trial in stroke disability (PISCES)
    • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

Media Coverage

January 2021 – Proactive Investors: ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy
July 2020 – Proactive Investors: ReNeuron’s Michael Hunt says key focus now is to build dataset for retinal disease study
June 2020 – Proactive Investors: ReNeuron’s Michael Hunt explains new emphasis on its retinal and exosome technology programmes
May 2020 – Proactive Investors: ReNeuron’s Michael Hunt talks new potential for its CTX therapy in treating Huntington’s disease
April 2020 – Proactive Investors: ReNeuron looking at applications of its own technology to deliver virus vaccine
February 2020 – Proactive Investors: ReNeuron’s retinal treatment ‘appears to have sustained long-term beneficial effect’
December 2019 – Proactive Investors: ReNeuron in active on-going talks for further potential out-licence deals
October 2019 – Proactive Investors: ‘All systems go’ for ReNeuron’s retinitis pigmentosa programme as it looks to follow-up studies
Proactive Investors: ReNeuron makes key business development hire as it looks to build on licensing deals
Proactive Investors: “ReNeuron ‘very encouraged’ by positive retinitis pigmentosa study results”
Page 1 of 512345

Section: News

  • News Centre
  • News
    • News Archive
  • Events
  • Media Coverage

Filter by:

  • Corporate
  • Product
    • Induced pluripotent stem cell (iPSC) Platform
    • CTX cells for Stroke Disability
    • CTX cells for Critical Limb Ischaemia
    • hRPCs for Retinitis Pigmentosa
    • CTX-derived Exosomes
  • Trial
    • Phase III clinical trial in stroke disability (PISCES-III)
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase II clinical trial in stroke disability (PISCES-II)
    • Observational study in stroke
    • Phase I trial in critical limb ischaemia
    • Phase I/II clinical trial in retinitis pigmentosa

Subscribe here for our Press Releases:

The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: 

© ReNeuron Group plc 2021 All rights reserved

Website design by Carr Kamasa Design

  • Privacy Notice
  • Disclaimer